<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4597">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592835</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1516101_Australia</org_study_id>
    <nct_id>NCT04592835</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Single-ascending Dose Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Following Intramuscular Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety, tolerability and Pharmacokinetic Properties of&#xD;
      Niclosamide Injectable (DWRX2003) in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 19, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 13, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>follow-up 35 days after dosing</time_frame>
    <description>Incidence, severity and causality of adverse events (AEs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess PK parameters of niclosamide injectable (DWRX2003) through Cmax</measure>
    <time_frame>at Day 1, 2, 3, 5, 7, 10, 14, 21 and 28</time_frame>
    <description>Measured through Maximum (peak) plasma drug concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess PK parameters of niclosamide injectable (DWRX2003) through tmax</measure>
    <time_frame>at Day 1, 2, 3, 5, 7, 10, 14, 21 and 28</time_frame>
    <description>Time to reach Cmax following IP administration (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess PK parameters of niclosamide injectable (DWRX2003) through AUC0-last</measure>
    <time_frame>at Day 1, 2, 3, 5, 7, 10, 14, 21 and 28</time_frame>
    <description>Area under the curve from zero to time of last measurable concentration (AUC0-last)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess PK parameters of niclosamide injectable (DWRX2003) through AUC0-∞</measure>
    <time_frame>at Day 1, 2, 3, 5, 7, 10, 14, 21 and 28</time_frame>
    <description>Area under the curve from zero to infinity (AUC0-∞)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess PK parameters of niclosamide injectable (DWRX2003) through t1/2</measure>
    <time_frame>at Day 1, 2, 3, 5, 7, 10, 14, 21 and 28</time_frame>
    <description>Elimination half-life (t1/2)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>COVID-19 Patients</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (288mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>72 mg/0.3 mL x 4 injection sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (576 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>144 mg/0.6 mL x 4 injection sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (960 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>216 mg/1.0 mL x 4 injection sites</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWRX2003</intervention_name>
    <description>Intramuscularly injection at predefined injection sites&#xD;
Drug: Placebo Intramuscularly injection at predefined injection sites</description>
    <arm_group_label>Cohort 1 (288mg)</arm_group_label>
    <arm_group_label>Cohort 2 (576 mg)</arm_group_label>
    <arm_group_label>Cohort 3 (960 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males and females, between 18 and 65 years of age, inclusive, at time of&#xD;
             signing the Informed Consent Form (ICF).&#xD;
&#xD;
          2. Body mass index between 18.0 lesser than or equal to Body Mass Index (BMI) lesser than&#xD;
             or equal to 32 at Screening, with a minimum weight of 50 kg (inclusive).&#xD;
&#xD;
          3. Willing to sign ICF on a voluntary basis and to voluntarily participate in the study,&#xD;
             after being fully informed of and completely understanding this study, prior to any&#xD;
             Screening procedure being undertaken&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating at Screening or planning to become pregnant (self or partner) at&#xD;
             any time during the study, including the follow-up period;&#xD;
&#xD;
          2. History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance, unless approved by the Investigator (or designee). Please&#xD;
             note participants with allergies which can be managed without treatment can be&#xD;
             included based on the decision of the Investigator (or designee).&#xD;
&#xD;
          3. Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the Investigator (or designee)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

